| Drug-Induced Adverse Reactions | Lifetime | 29 | KR 1 | 99.08 |
| Occupational exposure and asthma | Lifetime | 28 | KR 1 | 99.09 |
| Asthma and respiratory diseases | Lifetime | 260 | KR 1 | 99.31 |
| Urticaria and Related Conditions | Lifetime | 92 | KR 1 | 98.92 |
| Indoor Air Quality and Microbial Exposure | Lifetime | 66 | KR 2 | 98.57 |
| Contact Dermatitis and Allergies | Lifetime | 98 | KR 1 | 98.79 |
| Allergic Rhinitis and Sensitization | Lifetime | 226 | KR 1 | 99.01 |
| Respiratory and Cough-Related Research | Lifetime | 187 | KR 1 | 98.79 |
| Eosinophilic Esophagitis | Lifetime | 422 | KR 2 | 97.82 |
| Mast cells and histamine | Lifetime | 276 | KR 1 | 96.95 |
| Food Allergy and Anaphylaxis Research | Lifetime | 326 | KR 2 | 97.63 |
| Dermatology and Skin Diseases | Lifetime | 628 | KR 8 | 97.10 |
| Inhalation and Respiratory Drug Delivery | Lifetime | 419 | KR 1 | 97.00 |
| IL-33, ST2, and ILC Pathways | Lifetime | 405 | KR 3 | 96.27 |
| Inflammatory mediators and NSAID effects | Lifetime | 819 | KR 12 | 95.86 |
| Pediatric health and respiratory diseases | Lifetime | 784 | KR 16 | 95.43 |
| Autoimmune Bullous Skin Diseases | Lifetime | 655 | KR 3 | 95.76 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 909 | KR 3 | 94.31 |
| Occupational and environmental lung diseases | Lifetime | 653 | KR 5 | 94.20 |
| Asthma and respiratory diseases | 2021-2025 | 141 | KR 2 | 98.67 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 62 | KR 3 | 95.34 |
| Respiratory and Cough-Related Research | 2021-2025 | 102 | KR 2 | 96.43 |
| Urticaria and Related Conditions | 2021-2025 | 104 | KR 1 | 95.42 |
| Drug-Induced Adverse Reactions | 2021-2025 | 91 | KR 2 | 93.30 |
| Eosinophilic Esophagitis | 2021-2025 | 294 | KR 4 | 93.48 |
| Allergic Rhinitis and Sensitization | 2021-2025 | 514 | KR 10 | 91.94 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 228 | KR 6 | 90.45 |
| Pediatric health and respiratory diseases | 2021-2025 | 485 | KR 33 | 79.93 |
| Autoimmune Bullous Skin Diseases | 2021-2025 | 719 | KR 4 | 81.11 |
| Mast cells and histamine | 2021-2025 | 349 | KR 2 | 80.18 |
| Occupational exposure and asthma | 2021-2025 | 498 | KR 9 | 62.14 |